drugset / Trial / NCT06780839
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Phase 2
Not yet recruiting
70 enrolled
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of ensartinib on adjuvant therapy guided by MRD in IA3-IIIB (T3N2) stage ALK-positive non-small cell lung cancer patients.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2029-01-15
- Completion
- 2030-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ensartinib | Small molecule | 225 mg | — |